Market Place
Sourcing Support
Harbour BioMed Appoints Dr. Raymond as Chief Business Officer
14 Nov 2024 //
PR NEWSWIRE
Harbour BioMed Submits IND for HBM9378 in COPD Treatment
08 Nov 2024 //
PR NEWSWIRE
Harbour BioMed Publishes Phase I Study Results For Porustobart
09 Oct 2024 //
PR NEWSWIRE
Harbour BioMed Presents HBM1020 Clinical Data At ESMO Congress 2024
14 Sep 2024 //
PR NEWSWIRE
Harbour BioMed Announces 2024 Interim Results
28 Aug 2024 //
PR NEWSWIRE
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
18 Jul 2024 //
PR NEWSWIRE
Harbour BioMed Resubmits Batoclimab Biologics License For Myasthenia Gravis
26 Jun 2024 //
PR NEWSWIRE
Harbour BioMed Reports Full Year 2023 Financial Results
28 Mar 2024 //
PR NEWSWIRE
Harbour BioMed Announces Positive Profit Alert
18 Jan 2024 //
PR NEWSWIRE
Harbour IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
28 Aug 2023 //
PR NEWSWIRE
Harbour BioMed Announces 2023 Interim Results
28 Aug 2023 //
PR NEWSWIRE
Harbour Appoints Dr. Albert R. Collinson as Independent Non-Executive Director
08 Aug 2023 //
PR NEWSWIRE
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert
13 Jul 2023 //
PR NEWSWIRE
Harbour BioMed Announces BLA Acceptance of Batoclimab for Myasthenia Gravis
29 Jun 2023 //
PR NEWSWIRE
Harbour BioMed Announces First Patient Dosed in Phase I Study of HBM1020
04 Jun 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.